News
Announcement of Interview Articles Related to Our Company in Nature Biotechnology and Nature Reviews Drug Discovery
Our company is developing the plasminogen activator inhibitor 1 (PAI-1) inhibitor RS5614 for the cancer and anti-aging/longevity fields. We are pleased to announce that interview articles related to RS5614 in the cancer and anti-aging/longevity fields, titled “Targeting plasminogen activator inhibitor 1 for cancer and longevity,” have been published in the international scientific journals Nature Biotechnology (Vol. 43, No. 12, pp. B38-39) and Nature Reviews Drug Discovery (Vol. 24, No. 12, pp. B38-39) (Biopharma Dealmakers). The articles summarize the development history of RS5614, its pharmacological effects on cancer and anti-aging/longevity, the current status of clinical trials, and future prospects. The content is the same as the interview article in the December 4, 2025 issue of Nature (disclosed on December 1, 2025).